About Ophthalmology sector in Asia
The Ophthalmology sector in Asia comprises 275 companies, including 167 funded companies having collectively raised $1.58B in venture capital money and private equity. Out of these, 77 are Series A+ funded.
Ophthalmology sector in Asia has seen 4 acquisitions and 18 IPOs. This represents almost 8.0% of all such companies - which is higher than the 5.3% exit rate of tech companies in general.
This sector includes medical devices, diagnostics tests, and pharmaceuticals for the diagnosis and treatment of ophthalmological disorders.
Ophthalmology sector is also known as Ophthalmic Devices, Eye Care or Vision Care.
Medical devices, diagnostics tests, and pharmaceuticals for the diagnosis and treatment of ophthalmological disorders are included in this sector. Healthcare Service Providers, Digital Health Solutions (software, apps, online platforms) are excluded.
Top Ophthalmology Companies in Asia
There are 275 Ophthalmology startups in Asia which include Remidio, Forus Health, Remegen, Eyestem, NovaSight. Out of these, 167 startups are funded, with 77 having secured Series A+ funding.
Over the past 10 years, an average of 12 new companies have been launched annually. Notably, several of these startups have been founded by alumni of Tel Aviv University, Technion Israel Institute Technology and IIT Bombay.
Here is the list of top Ophthalmology startups in Asia
1. Remidio
Developer of AI-powered portable digital solutions for ophthalmic screening and diagnosis. The company specializes in eye testing using AI and telemedicine integrated to develop ophthalmic devices which include Fundus on phone (FOP-NM), Portable slit lamp (PSL-D20), Instaref R20, Anterior Imaging Module (AIM), and Microscope Recording Device (MRD).
Key facts about Remidio
- Founded Year: 2009
- Location: Bengaluru (India)
- Stage: Series B
- Total Funding till date: $25M
- Investors: Montane Ventures, Cipher-Plexus and 33 Others
- Latest Funding Round: Series B, Feb 19, 2023, $*****
- Tracxn Score: 67/100 What is this?
- Competitors Rank: 1 of 95 Competitors
2. Forus Health
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms. These devices are designed for acquiring, storing, and transmitting images of the eye's anterior and posterior segments, facilitating the diagnosis of various ocular diseases. The cloud-based platform integrates with the imaging devices, enabling remote diagnosis and efficient monitoring of patients. The company's technology aims to improve access to eye care, particularly in underserved areas. The devices are designed for ease of use and affordability, making them suitable for a wide range of healthcare settings.
Key facts about Forus Health
- Founded Year: 2010
- Location: Bengaluru (India)
- Stage: Series B
- Total Funding till date: $18.1M
- Investors: Chiratae Ventures, Accel and 14 Others
- Latest Funding Round: Series B, Jan 09, 2020, $*****
- Tracxn Score: 66/100 What is this?
- Competitors Rank: 2 of 176 Competitors
3. Remegen
Remegen is a developer of therapies for the treatment of cancer, autoimmune and eye diseases. Its technology is based on antibody and fusion proteins, antibody-drug conjugates (ADCs), and bifunctional antibodies therapies. The platform has developed drug candidate R18 that is the fusion protein for the rheumatoid arthritis treatment.
Key facts about Remegen
- Founded Year: 2008
- Location: Yantai (China)
- Stage: Public
- Total Funding till date: $100M
- Investors: Lilly Asia Ventures, CDG Capital and 10 Others
- Latest Funding Round: PE, Mar 16, 2020, $*****
- Tracxn Score: 61/100 What is this?
- Competitors Rank: 136 of 3,894 Competitors
4. Eyestem
Developer of cell replacement therapies to treat ophthamological conditions. The company's product line include Eyecyte-RPE is a suspension of retinal pigment epithelium cells derived from human induced pluripotent stem cells. The therapy aims to replace damaged RPE cells in the retina, which are critical in Dry AMD, potentially arresting and reversing vision loss.
Key facts about Eyestem
- Founded Year: 2015
- Location: Bengaluru (India)
- Stage: Series B
- Total Funding till date: $19.9M
- Investors: Kotak Investment Advisors, Endiya Partners and 24 Others
- Latest Funding Round: Series B, Aug 11, 2025, $*****
- Tracxn Score: 61/100 What is this?
- Competitors Rank: 3 of 76 Competitors
5. NovaSight
Provider of eye-tracking-based solutions for vision assessment and treatment. It offers medical devices to prevent vision impairments among pediatric patients using eye-tracking-based technology in novel diagnostic, therapeutic, and preventive solutions. Its products include CureSight an amblyopia treatment system, designed to replace traditional eye patching, TrackSight a software-based vision health monitoring and myopia prevention system, and Eye swift an eye-tracking-based vision diagnostics system.
Key facts about NovaSight
- Founded Year: 2016
- Location: Lod (Israel)
- Stage: Series B
- Total Funding till date: $20M
- Investors: Rimonci and EIT Health
- Latest Funding Round: Series B, Mar 12, 2022, $*****
- Tracxn Score: 61/100 What is this?
- Competitors Rank: 1 of 119 Competitors
Companies founded year-on-year in the Ophthalmology sector in Asia
26 Ophthalmology startups in Asia were founded in 2018 - this is the most number of startups founded in any year in the last 10 years.
- Total Number of Companies
Year | No. of companies |
|---|---|
2025 | - |
2024 | - |
2023 | 3 |
2022 | 7 |
2021 | 14 |
2020 | 13 |
2019 | 19 |
2018 | 26 |
2017 | 22 |
2016 | 18 |
Stage-wise distribution of Ophthalmology sector companies in Asia
Out of the total 275 Ophthalmology companies in Asia, 167 have secured funding. Among them, 77 have reached Series A or higher, and 54 to Series B or beyond.
Founded - 275
Funded - 167
Series A+ - 77
Series B+ - 54
Series C+ - 37
Company Stage | No. of companies |
|---|---|
Founded | 275 |
Funded | 167 |
Series A+ | 77 |
Series B+ | 54 |
Series C+ | 37 |
Let us walk you through our Sectors and other offerings
Designed with precision for VCs, PE, IBs, Incubators, M&A, Innovation more
Designed with precision for VCs, PE, IBs, Incubators, M&A, Innovation more
Funding Trends in the Ophthalmology sector in Asia
Total funding year-on-year in the Ophthalmology sector in Asia
The Ophthalmology sector in Asia saw a total funding of more than $1.5B in the last 10 years. The most amount of funding was in 2022 at more than $379M.
- Total Funding
Year | Total Funding |
|---|---|
2025 | $194M |
2024 | $137M |
2023 | $106M |
2022 | $379M |
2021 | $262M |
2020 | $257M |
2019 | $10.3M |
2018 | $63.1M |
2017 | $80.9M |
Recent Funding Rounds in Ophthalmology in Asia
In the year 2025, till September 2025, Ophthalmology companies in Asia have raised $194M in equity funding across 11 rounds.
In the same period last year (i.e. till July 2024), Ophthalmology companies in Asia had raised $31.7M across 13 rounds.
So, 2025 has seen a 509.58% rise in funding in Ophthalmology companies in Asia as compared to 2024.
Here are some recent, important funding rounds in Ophthalmology companies in Asia:
Company | Round Raised | Amount Raised | Funding Date | Investors |
|---|---|---|---|---|
Series B | 8484 | Sep 04, 2025 | ||
Series A | 2034 | Aug 18, 2025 | ||
Series B | 8157 | Aug 11, 2025 | and 3 more | |
Series B | 1735 | Jul 31, 2025 | ||
Seed | 3529 | Jul 01, 2025 |
Top Investors in Ophthalmology in Asia
Orbimed is the top investor in Ophthalmology companies in Asia based on number of companies invested.
Here are some top investors in Ophthalmology companies in Asia:
Investor | Location | Top Portfolio Companies |
|---|---|---|
New York City (United States) | ||
Hellerup (Denmark) | - | |
Washington, DC (United States) | - | |
New York City (United States) | - | |
Delhi (India) |
M&A activity in Ophthalmology sector in Asia
In the year 2024, till July 2024, 1 acquisition happened in Ophthalmology sector in Asia.
Here are some recent, important acquisitions in Ophthalmology sector in Asia:
Company | Acquisition Type | Acquisition Date | Acquirers |
|---|---|---|---|
Business Acquisition | Jul 01, 2024 | ||
Business Acquisition | Aug 08, 2022 | ||
Acqui-Hired | Dec 14, 2009 | ||
Management Buyout | Oct 2005 | - |
Acquisition trends in Ophthalmology sector in Asia
Here are the acquisition trends in Ophthalmology sector in Asia:
- Total Number of Acquisitions
Year | No. of companies |
|---|---|
2025 | - |
2024 | 1 |
2023 | - |
2022 | 1 |
2021 | - |
2020 | - |
2019 | - |
2018 | - |
2017 | - |
2016 | - |
IPOs in Ophthalmology in Asia
In the year 2025, till March 2025, 1 IPO happened in Ophthalmology sector in Asia.
Here are some recent, important IPOs in Ophthalmology sector in Asia:
Company | IPO Date | Exchange Symbol |
|---|---|---|
Mar 10, 2025 | Taipei Stock Exchange (TT) | |
Dec 09, 2024 | Canadian Securities Exchange (CSE) | |
Dec 02, 2022 | Taipei Stock Exchange (TT) | |
Jun 23, 2022 | Tokyo Stock Exchange (TSE) | |
Apr 01, 2022 | Shanghai Stock Exchange (SSE) |
Colleges which produce the most Ophthalmology companies in Asia
Companies founded by alumni from top colleges in the Ophthalmology in Asia
Most number of Ophthalmology startups in Asia have been founded by alumni from Tel Aviv University, Technion Israel Institute Technology and IIT Bombay.
College | No. of companies |
|---|---|
Tel Aviv University | 11 |
Technion Israel Institute Technology | 5 |
IIT Bombay | 2 |
University of Cambridge | 2 |
BITS Pilani | 1 |
Carnegie Mellon University | 1 |
Columbia University | 1 |
Hong Kong University of Science and Technology (HKUST) | 1 |
IIM Calcutta | 1 |
IIT Delhi | 1 |
Total funding in Ophthalmology companies founded by alumni from top colleges in Asia
In the last 10 years, Technion Israel Institute Technology graduates' Ophthalmology companies in Asia have raised the most funding among top colleges. Tel Aviv University alumni are second, and IIT Delhi alumni are third.
College | Total Funding |
|---|---|
Technion Israel Institute Technology | $205M |
Tel Aviv University | $74.1M |
IIT Delhi | $25M |
IIT Kharagpur | $25M |
Massachusetts Institute of Technology | $25M |
BITS Pilani | $18.1M |
Indian Institute of Science | $18.1M |
University of Cambridge | $8M |
IIT Bombay | $3.45M |
Stanford University | $3.26M |
Top News in Ophthalmology in Asia
•
•
•
RemeGen's Bispecific Antibody RC148 Approved for Phase II Trial in US by FDAPR Newswire•Aug 08, 2025•FDA, Remegen
•
Lotte Biologics signs MoU to develop antibody-drug conjugates toolboxBioSpectrum Asia•Jun 18, 2025•LOTTE BIOLOGICS, Axcelead Drug Discovery Partners, Kanaph
•
RemeGen's Telitacicept Receives EMA Orphan Drug Designation for Myasthenia GravisPR Newswire•Jun 17, 2025•Remegen
•
•
•
•
•
Eyestem’s Eyecyte-RPE trial shows vision rescue for geographic atrophy patients
Indiatimes•Apr 14, 2025•Eyestem
